查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1236058

多发性硬化症治疗全球市场规模研究与预测：按药物类别、给药途径、分销渠道和地区分析，2022-2029 年

Global Multiple Sclerosis Drugs Market Size study & Forecast, by Drug Class by Route of Administration, by Distribution Channel and Regional Analysis, 2022-2029
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3个工作天内

价格

多发性硬化症是一种炎症性免疫介导的疾病，会影响大脑和脊髓中的神经元，导致轴突切断、脱髓鞘和神经变性。

最常用的治疗方法包括物理疗法、肌肉鬆弛剂、抗抑郁药、口服药物、注射剂和静脉注射。 这些包括富马酸二甲酯、特立氟胺和克拉曲滨等口服药物，ocrelizumab 等输液疗法，以及肌肉或皮下注射的干扰素-BETA 和醋酸格拉替雷等注射疗法。 市场增长的主要驱动力是多发性硬化症患病率上升和市场开发研发投资增加，预计这将在预测期内支持市场增长。

根据多发性硬化症国际联合会 (MSIF) 的数据，全球多发性硬化症患者人数将从 2013 年的 230 万增加到 2020 年的 280 万。 随着该病患病率的增加，全世界对多发性硬化症有效诊断和治疗的需求不断增加。 此外，市场参与者增加研发和临床试验也有望为市场创造有利的需求。 例如，赛诺菲正在进行trebrutinib（PPMS）治疗非复发性继发进展性多发性硬化症（nrSPMS）、復发性多发性硬化症（RMS）和原发性进展性多发性硬化症的三期临床试验。 赛诺菲预计将分别在 2024 年和 2025 年提交该药物用于其批准的适应症。 此外，预计政府对多发性硬化症治疗的支持增加将在预测期内推动市场增长。 然而，多发性硬化症治疗的高成本将阻碍整个 2022-2029 年预测期内的市场增长。

多发性硬化症治疗药物全球市场研究考虑的主要区域是亚太地区、北美、欧洲、拉丁美洲和世界其他地区。 由于研发投入增加、新产品开发以及对免疫抑製剂和分子抗体药物的需求不断增长，北美已成为全球市场份额的领导者。 另一方面，由于多发性硬化症患病率增加以及多个国家政府加大力度降低治疗费用等因素，亚太地区在预测期内将出现高增长率。预计将显示

市场近期发展

  • 2021 年 3 月，Janssen Pharmaceuticals 获得美国 FDA 批准 Ponvory，这是一种口服特异性 1-磷酸鞘氨醇受体 1 (S1P1) 调节剂，用于治疗復发性 MS 患者。澄清。 与Aubagio相比，Ponvory在降低年復发率方面更有效。 通过将该产品添加到其产品组合中，该公司扩大了其治疗 MS 的产品系列。

全球市场报告范围

  • 历史数据：2019-2020-2021
  • 估算基准年：2021 年
  • 预测期：2022-2029
  • 报告范围：收入预测、公司排名、竞争格局、增长因素、趋势
  • 按地区划分：北美、欧洲、亚太地区、拉丁美洲、世界其他地区
  • 定制范围：免费报告定制（最多 8 个工作小时）。 按国家、地区和部门划分的范围的添加和更改。

本研究的目的是弄清近年来各个领域和国家的市场规模，并对未来几年的市场规模进行预测。 该报告旨在捕捉被调查国家工业的定性和定量方面的情况。

它还提供了关键方面的详细信息，例如决定市场未来增长的驱动因素和挑战。 此外，它还结合了利益相关者投资的潜在微观市场机会，以及主要参与者的竞争格局等详细分析。

内容

第 1 章执行摘要

  • 市场概况
  • 2019-2029 年各细分市场的全球市场估计和预测
    • 多发性硬化症治疗市场，按地区划分，2019-2029 年
    • 多发性硬化症治疗市场，按药物类别，2019-2029 年
    • 按给药途径划分的多发性硬化症药物市场，2019-2029 年
    • 多发性硬化症治疗市场，按分销渠道，2019-2029 年
  • 主要趋势
  • 调查方法
  • 调查先决条件

第 2 章。全球多发性硬化症治疗市场的定义和范围

  • 调查目的
  • 市场定义和范围
    • 调查范围
    • 工业发展
  • 调查年份
  • 货币兑换率

第 3 章多发性硬化症药物的全球市场动态

  • 多发性硬化症药物市场影响分析 (2019-2029)
    • 市场驱动力
      • 多发性硬化症患病率上升
      • 增加研发投资
    • 市场挑战
      • 多发性硬化症药物价格上涨
    • 市场机会
      • 政府对多发性硬化症治疗的支持越来越多

第 4 章多发性硬化症药物全球市场行业分析

  • 波特 5 力模型
    • 供应商的议价能力
    • 买家的议价能力
    • 新进入者的威胁
    • 替代品的威胁
    • 竞争公司之间的敌对关係
  • 波特 5 力模型的未来方法 (2019-2029)
  • 害虫分析
    • 政治
    • 经济的
    • 社交
    • 技术
  • 最佳投资机会
  • 关键成功策略
  • 业内人士的前景
  • 分析师的建议和结论

第 5 章风险评估 COVID-19 影响

  • 评估 COVID-19 对行业的总体影响
  • COVID-19 之前和 COVID-19 之后的市场情景

第 6 章。多发性硬化症药物的全球市场：按药物类别分类

  • 市场概况
  • 多发性硬化症治疗药物的全球市场：按药物类别、性能潜力分析
  • 2019-2029 年按药物类别划分的多发性硬化症药物全球市场估计和预测
  • 多发性硬化症药物市场细分分析
    • 免疫调节剂
    • 免疫抑製剂
    • 干扰素

第 7 章。多发性硬化症药物的全球市场：按给药途径分类

  • 市场概况
  • 多发性硬化症药物的全球市场：按给药途径进行的性能潜力分析
  • 2019-2029 年多发性硬化症药物全球市场估计和预测（按给药途径）
  • 多发性硬化症药物市场细分分析
    • 口语
    • 注射

第 8 章。全球多发性硬化症药物市场：按分销渠道分类

  • 市场概况
  • 多发性硬化症药物的全球市场：按分销渠道进行的性能潜力分析
  • 2019-2029 年多发性硬化症药物全球市场估计和预测（按分销渠道）
  • 多发性硬化症药物市场细分分析
    • 医院药房
    • 零售药房
    • 在线药店

第 9 章。多发性硬化症药物的全球市场：区域分析

  • 多发性硬化症药物市场，按地区划分的市场概况
  • 北美
    • 美国
      • 2019-2029 年按药物类别的估计和预测
      • 按给药途径估算和预测，2019-2029 年
      • 2019-2029 年各分销渠道的估计和预测
    • 加拿大
  • 欧洲多发性硬化症药物市场概况
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 意大利
    • 其他欧洲
  • 亚太地区多发性硬化症药物市场概况
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 韩国
    • 其他亚太地区
  • 拉丁美洲多发性硬化症药物市场概况
    • 巴西
    • 墨西哥
    • 其他拉丁美洲地区
  • 世界其他地方

第 10 章衝突信息

  • 顶级市场策略
  • 公司简介
    • 百健公司
      • 关键信息
      • 概览
      • 财务（仅当数据可用时）
      • 产品概览
      • 近期趋势
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • Merck & Co., Inc.
    • Sanofi S.A.
    • Teva Pharmaceutical Industries Ltd.
    • Janssen Pharmaceuticals, Inc.（Johnson & Johnson Corporation）
    • Bristol-Myers Squibb Company
    • Cipla Inc.

第 11 章研究过程

  • 研究过程
    • 数据挖掘
    • 分析
    • 市场评估
    • 验证
    • 出版
  • 调查的特点
  • 调查先决条件

Global Multiple Sclerosis Drugs Market is valued approximately USD XXX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XXX% over the forecast period 2022-2029. Multiple sclerosis is an inflammatory immune-mediated disorder that affects nerve cells in the brain and the spinal cord, causing axonal transection, demyelination, and neurodegeneration. Some of the most often used treatments include physical therapy, muscle relaxants, antidepressants, and oral, injectable, and infused medications. Oral drugs including dimethyl fumarate, teriflunomide, and cladribine; intravenous infusion therapies like ocrelizumab; and injectable therapies like interferon-beta, glatiramer acetate, given intramuscularly or subcutaneously. The key factor driving the market growth is rising prevalence of Multiple Sclerosis disease and rising R&D investment by the market players for the drugs development that anticipated to support the market growth during forecast period.

According to the Multiple Sclerosis International Federation (MSIF), the number of patients with multiple sclerosis throughout the globe increased from 2.3 million in 2013 to 2.8 million in 2020. The demand for effective multiple sclerosis diagnosis and treatment has increased worldwide as a result of the disease's rising prevalence. Also, the rising R&D and clinical trial by the market players will create the lucrative demand for the market. For instance, For the therapy of non-relapsing secondary progressive MS (nrSPMS), relapsing forms of MS (RMS), and primary progressive MS, Sanofi is conducting a phase III clinical trial for tolebrutinib (PPMS). Sanofi anticipates submitting this medication in 2024 and 2025+, respectively, for the approved indications. Additionally, the rising government support for the treatment of multiple sclerosis is likely to increase the market growth during the forecast period. However, the high cost of Multiple Sclerosis Drugs stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Multiple Sclerosis Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the dominating region across the world in terms of market share, owing to the rising R&D investment, new product development, and growing demand for immunosuppressant and molecular antibody drugs. Whereas, Asia Pacific is also anticipated to exhibit highest growth rate over the forecast period, owing to factors such as growing prevalence of multiple sclerosis disease and rising government initiatives in several countries to reduce the cost of treatment would create lucrative growth prospects for the Multiple Sclerosis Drugs market across Asia Pacific region.

Major market players included in this report are:

  • Biogen Inc.
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Merck & Co., Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation)
  • Bristol-Myers Squibb Company
  • Cipla Inc.

Recent Developments in the Market:

  • In March 2021, Janssen Pharmaceutical, Inc. revealed the U.S. FDA approval of Ponvory, an oral specific sphingosine-1-phosphate receptor 1 (S1P1) modulator to treat people with relapsing forms of MS. In comparison to Aubagio, Ponvory is more effective at lowering annual relapse rates. The company increased its range of products for the treatment of MS with the inclusion of this product in its portfolio.

Global Multiple Sclerosis Drugs Market Report Scope:

  • Historical Data: 2019-2020-2021
  • Base Year for Estimation: 2021
  • Forecast period: 2022-2029
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Drug Class, Route of Administration, Distribution Channel, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Class:

  • Immunomodulators
  • Immunosuppressants
  • Interferons

By Route of Administration:

  • Oral
  • Injection

By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • RoLA
  • Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Multiple Sclerosis Drugs Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Multiple Sclerosis Drugs Market, by Drug Class, 2019-2029 (USD Billion)
    • 1.2.3. Multiple Sclerosis Drugs Market, by Route of Administration, 2019-2029 (USD Billion)
    • 1.2.4. Multiple Sclerosis Drugs Market, by Distribution Channel, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Multiple Sclerosis Drugs Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Multiple Sclerosis Drugs Market Dynamics

  • 3.1. Multiple Sclerosis Drugs Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Rising prevalence of multiple sclerosis disease
      • 3.1.1.2. Growing R&D Investment
    • 3.1.2. Market Challenges
      • 3.1.2.1. High cost of multiple sclerosis drugs
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Rising government support for the treatment of multiple sclerosis

Chapter 4. Global Multiple Sclerosis Drugs Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. Industry Experts Prospective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Multiple Sclerosis Drugs Market, by Drug Class

  • 6.1. Market Snapshot
  • 6.2. Global Multiple Sclerosis Drugs Market by Drug Class, Performance - Potential Analysis
  • 6.3. Global Multiple Sclerosis Drugs Market Estimates & Forecasts by Drug Class 2019-2029 (USD Billion)
  • 6.4. Multiple Sclerosis Drugs Market, Sub Segment Analysis
    • 6.4.1. Immunomodulators
    • 6.4.2. Immunosuppressants
    • 6.4.3. Interferons

Chapter 7. Global Multiple Sclerosis Drugs Market, by Route of Administration

  • 7.1. Market Snapshot
  • 7.2. Global Multiple Sclerosis Drugs Market by Route of Administration, Performance - Potential Analysis
  • 7.3. Global Multiple Sclerosis Drugs Market Estimates & Forecasts by Route of Administration 2019-2029 (USD Billion)
  • 7.4. Multiple Sclerosis Drugs Market, Sub Segment Analysis
    • 7.4.1. Oral
    • 7.4.2. Injection

Chapter 8. Global Multiple Sclerosis Drugs Market, by Distribution Channel

  • 8.1. Market Snapshot
  • 8.2. Global Multiple Sclerosis Drugs Market by Distribution Channel, Performance - Potential Analysis
  • 8.3. Global Multiple Sclerosis Drugs Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Billion)
  • 8.4. Multiple Sclerosis Drugs Market, Sub Segment Analysis
    • 8.4.1. Hospital Pharmacy
    • 8.4.2. Retail Pharmacy
    • 8.4.3. Online Pharmacy

Chapter 9. Global Multiple Sclerosis Drugs Market, Regional Analysis

  • 9.1. Multiple Sclerosis Drugs Market, Regional Market Snapshot
  • 9.2. North America Multiple Sclerosis Drugs Market
    • 9.2.1. U.S. Multiple Sclerosis Drugs Market
      • 9.2.1.1. Drug Class breakdown estimates & forecasts, 2019-2029
      • 9.2.1.2. Route of Administration breakdown estimates & forecasts, 2019-2029
      • 9.2.1.3. Distribution Channel breakdown estimates & forecasts, 2019-2029
    • 9.2.2. Canada Multiple Sclerosis Drugs Market
  • 9.3. Europe Multiple Sclerosis Drugs Market Snapshot
    • 9.3.1. U.K. Multiple Sclerosis Drugs Market
    • 9.3.2. Germany Multiple Sclerosis Drugs Market
    • 9.3.3. France Multiple Sclerosis Drugs Market
    • 9.3.4. Spain Multiple Sclerosis Drugs Market
    • 9.3.5. Italy Multiple Sclerosis Drugs Market
    • 9.3.6. Rest of Europe Multiple Sclerosis Drugs Market
  • 9.4. Asia-Pacific Multiple Sclerosis Drugs Market Snapshot
    • 9.4.1. China Multiple Sclerosis Drugs Market
    • 9.4.2. India Multiple Sclerosis Drugs Market
    • 9.4.3. Japan Multiple Sclerosis Drugs Market
    • 9.4.4. Australia Multiple Sclerosis Drugs Market
    • 9.4.5. South Korea Multiple Sclerosis Drugs Market
    • 9.4.6. Rest of Asia Pacific Multiple Sclerosis Drugs Market
  • 9.5. Latin America Multiple Sclerosis Drugs Market Snapshot
    • 9.5.1. Brazil Multiple Sclerosis Drugs Market
    • 9.5.2. Mexico Multiple Sclerosis Drugs Market
    • 9.5.3. Rest of Latin America Multiple Sclerosis Drugs Market
  • 9.6. Rest of The World Multiple Sclerosis Drugs Market

Chapter 10. Competitive Intelligence

  • 10.1. Top Market Strategies
  • 10.2. Company Profiles
    • 10.2.1. Biogen Inc.
      • 10.2.1.1. Key Information
      • 10.2.1.2. Overview
      • 10.2.1.3. Financial (Subject to Data Availability)
      • 10.2.1.4. Product Summary
      • 10.2.1.5. Recent Developments
    • 10.2.2. Pfizer Inc.
    • 10.2.3. F. Hoffmann-La Roche Ltd.
    • 10.2.4. Novartis AG
    • 10.2.5. Merck & Co., Inc.
    • 10.2.6. Sanofi S.A.
    • 10.2.7. Teva Pharmaceutical Industries Ltd.
    • 10.2.8. Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation)
    • 10.2.9. Bristol-Myers Squibb Company
    • 10.2.10. Cipla Inc.

Chapter 11. Research Process

  • 11.1. Research Process
    • 11.1.1. Data Mining
    • 11.1.2. Analysis
    • 11.1.3. Market Estimation
    • 11.1.4. Validation
    • 11.1.5. Publishing
  • 11.2. Research Attributes
  • 11.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Multiple Sclerosis Drugs Market, report scope
  • TABLE 2. Global Multiple Sclerosis Drugs Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Multiple Sclerosis Drugs Market estimates & forecasts by Drug Class 2019-2029 (USD Billion)
  • TABLE 4. Global Multiple Sclerosis Drugs Market estimates & forecasts by Route of Administration 2019-2029 (USD Billion)
  • TABLE 5. Global Multiple Sclerosis Drugs Market estimates & forecasts by Distribution Channel 2019-2029 (USD Billion)
  • TABLE 6. Global Multiple Sclerosis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 7. Global Multiple Sclerosis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Multiple Sclerosis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Multiple Sclerosis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Multiple Sclerosis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Multiple Sclerosis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Multiple Sclerosis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Multiple Sclerosis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. Global Multiple Sclerosis Drugs Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. Global Multiple Sclerosis Drugs Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 16. U.S. Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 17. U.S. Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 18. U.S. Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 19. Canada Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 20. Canada Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 21. Canada Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 22. UK Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 23. UK Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 24. UK Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 25. Germany Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 26. Germany Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 27. Germany Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 28. France Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 29. France Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 30. France Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 31. Italy Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 32. Italy Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 33. Italy Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 34. Spain Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 35. Spain Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 36. Spain Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 37. RoE Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 38. RoE Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 39. RoE Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 40. China Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 41. China Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 42. China Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 43. India Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 44. India Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 45. India Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 46. Japan Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 47. Japan Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 48. Japan Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 49. South Korea Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 50. South Korea Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 51. South Korea Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 52. Australia Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 53. Australia Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 54. Australia Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 55. RoAPAC Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 56. RoAPAC Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 57. RoAPAC Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 58. Brazil Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 59. Brazil Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 60. Brazil Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 61. Mexico Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 62. Mexico Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 63. Mexico Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 64. RoLA Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 65. RoLA Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 66. RoLA Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 67. Row Multiple Sclerosis Drugs Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 68. Row Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 69. Row Multiple Sclerosis Drugs Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 70. List of secondary sources, used in the study of global Multiple Sclerosis Drugs Market
  • TABLE 71. List of primary sources, used in the study of global Multiple Sclerosis Drugs Market
  • TABLE 72. Years considered for the study
  • TABLE 73. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Multiple Sclerosis Drugs Market, research methodology
  • FIG 2. Global Multiple Sclerosis Drugs Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Multiple Sclerosis Drugs Market, key trends 2021
  • FIG 5. Global Multiple Sclerosis Drugs Market, growth prospects 2022-2029
  • FIG 6. Global Multiple Sclerosis Drugs Market, porters 5 force model
  • FIG 7. Global Multiple Sclerosis Drugs Market, pest analysis
  • FIG 8. Global Multiple Sclerosis Drugs Market, value chain analysis
  • FIG 9. Global Multiple Sclerosis Drugs Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Multiple Sclerosis Drugs Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Multiple Sclerosis Drugs Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Multiple Sclerosis Drugs Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Multiple Sclerosis Drugs Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Multiple Sclerosis Drugs Market, regional snapshot 2019 & 2029
  • FIG 15. North America Multiple Sclerosis Drugs Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Multiple Sclerosis Drugs Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia pacific Multiple Sclerosis Drugs Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Multiple Sclerosis Drugs Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Multiple Sclerosis Drugs Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable